Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: BMS is a global biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical and related health care products. The company operates two primary reportable segments: Pharmaceuticals and Nutritionals (Mead Johnson Nutritionals). During the period, BMS executed a strategy to transform into a next-generation biopharmaceutical company, highlighted by the divestiture of its ConvaTec business and the planned partial IPO of Mead Johnson Nutritionals.
Key Financial Metrics
| Metric (in millions) | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 |
|---|---|---|
| Net Sales | $5,254 | $15,348 |
| Net Earnings (Total) | $2,578 | $4,003 |
| Net Earnings from Continuing Operations | $588 | $1,957 |
| Diluted EPS (Total) | $1.29 | $2.00 |
| Diluted EPS (Continuing Ops) | $0.30 | $0.98 |
| Operating Cash Flow | $1,400 (Q3 est.) | $3,341 |
| Cash and Cash Equivalents | $7,173 | $7,173 |
| Long-Term Debt | $6,120 | $6,120 |
| Working Capital | $7,828 | $7,828 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 14% in Q3 2008 and 17% for the nine-month period compared to 2007. Growth was driven by Pharmaceuticals (up 15% in Q3) and Nutritionals (up 10% in Q3), aided by favorable foreign exchange impacts.
- Discontinued Operations Impact: Total Net Earnings were significantly boosted by a $1.982 billion gain on the disposal of the ConvaTec business in Q3 2008. Excluding discontinued operations, Net Earnings from Continuing Operations decreased 22% in Q3 2008 compared to Q3 2007.
- Impairment Charges: The company recorded a $224 million impairment charge in Q3 2008 related to Auction Rate Securities (ARS), compared to no such charge in the prior year. Total ARS impairment for the nine months was $247 million.
- Restructuring Costs: Charges associated with the Productivity Transformation Initiative (PTI) totaled $107 million in Q3 2008 and $329 million for the nine months, compared to $44 million for the nine months in 2007.
- Debt Management: Long-term debt increased to $6.1 billion from $4.4 billion at year-end 2007, primarily due to the issuance of $1.6 billion in new notes in May 2008, partially offset by the repayment of $1.15 billion in convertible debentures.
Guidance, Outlook, and Risks
- Strategic Outlook: Management remains on track to achieve $1.5 billion in annual cost savings by 2010 through the PTI. An expansion of the initiative targets an additional $1.0 billion in savings by 2012.
- Divestitures: The company completed the sale of ConvaTec for approximately $4.1 billion. It plans to sell 10-20% of Mead Johnson Nutritionals via IPO while retaining an 80% interest.
- Investment Portfolio Risk: Significant risk exists regarding the valuation of Auction Rate Securities (ARS) and Floating Rate Securities (FRS) due to illiquidity in credit markets. The company recorded $247 million in impairments for the nine months and holds $213 million in ARS and $178 million in FRS at fair value. Further impairments are possible if market conditions deteriorate.
- Patent Litigation: PLAVIX*, the company's largest product, faces patent challenges in the U.S. and Europe. Data protection expired in the EU in July 2008, leading to generic competition in some markets. The company is vigorously defending its patents.
- Legal Contingencies: The company is involved in various litigation matters, including pricing practices (AWP), securities litigation regarding PLAVIX settlement disclosures, and product liability claims.
Investor Verification Checklist
- Continuing Operations Performance: Verify the trend in Net Earnings from Continuing Operations ($588M Q3 2008 vs $753M Q3 2007) to assess core business health independent of the ConvaTec sale.
- Investment Portfolio Valuation: Review the status of the $213 million ARS and $178 million FRS holdings for potential future impairment charges given market liquidity concerns.
- PLAVIX* Patent Status: Monitor ongoing litigation outcomes in the U.S. and EU, as loss of exclusivity would materially impact future revenue.
- PTI Cost Savings: Track the realization of the $1.5 billion cost savings target and the costs associated with the expanded 2012 initiative.
- Dividend Sustainability: Confirm the ability to maintain the dividend ($0.31 per share in Q3) amidst restructuring costs and potential investment impairments.